Augusto Focil
Family Medicine · Oxnard, CANPI 1407906027
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by AbbVie at 53.0% of the total. Reporting peaked in 2022 at $3,926 and has fallen 98.7% since, to $50 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$776
- Novo Nordisk$344
- Sanofi-aventis U.S. LLC$269
- Boehringer Ingelheim$267
- Mannkind Corporation$235
- plus $1K from 18 others
Across 1,053 payments — averaging $11,977 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$4.5M
- Modernatx, Inc.$3.3M
- Pfizer$887K
- Boehringer Ingelheim International GmbH$861K
- GSK$752K
- Gilead$473K
- plus $1.8M from 9 others
What the payments were for
- Speaking & faculty fees$3,36052%
- Food & beverage$3,05647%
- Education$501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 4 | $3,427 |
| AstraZeneca | 42 | $776 |
| Novo Nordisk | 22 | $344 |
| Sanofi-aventis U.S. LLC | 13 | $269 |
| Boehringer Ingelheim | 9 | $267 |
| Mannkind Corporation | 20 | $235 |
| Johnson & Johnson | 19 | $193 |
| Novartis | 9 | $147 |
| Merck | 6 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $110 |
| Bayer | 4 | $93 |
| Biohaven Pharmaceuticals, Inc. | 4 | $76 |
| Amarin Pharma, Inc. | 4 | $74 |
| Amgen | 3 | $65 |
| Abbott | 3 | $49 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Radius Health, Inc. | 2 | $41 |
| Janssen Scientific Affairs, LLC | 1 | $30 |
| Bioventus LLC | 1 | $26 |
| Arbor Pharmaceuticals, Inc. | 1 | $25 |
| Genentech USA, Inc. | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Pfizer | 2 | $16 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$3,360
How this compares
$6,466 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 148 | $96,549 |
| JardianceEmpagliflozin | 43 | $24,665 |
| VascepaIcosapent Ethyl | 49 | $18,807 |
| OzempicSemaglutide | 19 | $17,058 |
| LinzessLinaclotide | 22 | $13,553 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $11,750 |
| JanuviaSitagliptin Phosphate | 19 | $11,521 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $8,072 |
| DapagliflozinDapagliflozin Propanediol | 15 | $7,844 |
| Ezetimibe | 170 | $5,104 |
| Dexlansoprazole DrDexlansoprazole | 17 | $4,011 |
| Rosuvastatin Calcium | 246 | $2,517 |
| Icosapent Ethyl | 13 | $2,454 |
| Atorvastatin Calcium | 285 | $1,577 |
| PaxlovidNirmatrelvir/Ritonavir | 12 | $1,429 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $776 | $96,549148 claims |
| Boehringer IngelheimJardiance | $267 | $24,66543 claims |
| Novo NordiskOzempic | $344 | $17,05819 claims |
| AbbVieLinzess | $3,427 | $13,55322 claims |
| MerckJanuvia | $115 | $11,52119 claims |
| PfizerPaxlovid | $16 | $1,42912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Oxnard
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.